CoChat
Sign Up
Cited by 265Growth Hormone and Insulin-like Growth FactorsGenetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesSexual Differentiation and Disorders

Growth hormone therapy of Turner's syndrome: beneficial effect on adult height

Rosenfeld, Ron G., Attie, Kenneth M., Frane, James, Brasel, Anne, Burstein, Stephen, Cara, Jose F., Chernausek, Steven, Gotlin, Ronald W. +6 more·1998·The Journal of Pediatrics
DOI 10.1016/s0022-3476(98)70452-4
Open this paper in CoChat — free account

Abstract

Objective To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (OX), in patients with Turner's syndrome (TS).Methods In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX, (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens.Results Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4+/-5.5 cm (mean +/- SD), 8.4+/-4.5 cm taller than their mean projected adult height at enrollment (95% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1+/-5.9 cm, 10.3+/-4.7 cm taller than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2+/-6.0 cm, precisely matching their original projected adult height of 144.2+/-6.1 cm.Conclusions GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment, an adult height of more than 150 cm is a reasonable goal for most girls with TS.

Integrity signals

Registry

Crossref · 10.1016/s0022-3476(98)70452-4

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only six RCTs have compared GH treatment with concurrent non-treatment or placebo control for at least one year.

    “Despite numerous studies of GH treatment in TS, only six randomized, controlled trials (RCTs) have compared GH treatment with a concurrent non-treatment or placebo control for at least one year157-162”

    From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [159]

  • A 2007 Cochrane review concluded that girls treated with GH grew 3 cm/year more than untreated girls in the first 12-18 months.

    “a 2007 Cochrane Center review156 concluded that girls treated with GH grew 3 cm year−1 more than untreated girls in the first 12-18 months of therapy”

    From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [159]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Rosenfeld, R. G., Attie, K. M., Frane, J., Brasel, A., Burstein, S., Cara, J. F., Chernausek, S., Gotlin, R. W., Kuntze, J., Lippe, B. M., Mahoney, C. P., Moore, W. V., Saenger, P., & Johanson, A. J.
Affiliations
Oregon Health & Science University (US)
ORCID
Venue
The Journal of Pediatrics
Publisher
Elsevier BV
Published
1998-02
Volume
132
Issue
2
Pages
319-324
ISSN
0022-3476 (ISSN-L)
DOI
10.1016/s0022-3476(98)70452-4
OpenAlex
W2013492072
Cited by
265
References
19
Citations by year
2026: 2 · 2024: 7 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 8 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 7 · 2014: 8 · 2013: 9 · 2012: 6
FWCI
14.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Journal of Pediatrics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
Keywords
Turner syndrome, growth hormone therapy, oxandrolone, adult height, short stature, growth promotion, girls
MeSH terms
Body Height, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Oxandrolone, Prospective Studies, Growth Hormone, Turner Syndrome, Treatment Outcome, Anabolic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review